Syngene International expands its Biologics facility by incorporating new antibody-drug conjugate (ADC) bioconjugation capabilities. This strategic investment enables the company to provide fully integrated, end-to-end services for antibody-drug conjugates, from discovery through GMP manufacturing. The expansion enhances Syngene’s existing commercial capabilities in payload and linker manufacturing, accelerating development timelines. The investment is considered part of the ordinary course of business.
Biologics Facility Expansion
Syngene International is expanding its Biologics facility. The expansion adds new antibody-drug conjugate (ADC) bioconjugation capabilities. This allows the company to provide comprehensive services in this area.
Integrated Service Offering
The Company plans to offer fully integrated, end-to-end services for antibody-drug conjugates (ADCs). These services will span from discovery through GMP manufacturing. The expansion will speed up development timelines. This will be achieved by enabling both Monoclonal Antibodies (mAb) production and GMP bioconjugation at a single site. This also complements the Company’s existing capabilities in payload and linker manufacturing.
Strategic Investment
The company considers the investment in bioconjugation capabilities to be in the Ordinary Course of its business.
Source: BSE
